COVID-19 and the role of cytokines in this disease

被引:91
作者
Hasanvand, Amin [1 ]
机构
[1] Lorestan Univ Med Sci, Fac Med, Dept Physiol & Pharmacol, Khorramabad, Iran
关键词
COVID-19; Cytokines; Inflammatory response; INNATE LYMPHOID-CELLS; HIV PROTEASE INHIBITOR; GROWTH-FACTOR-BETA; T-CELLS; INFLAMMATORY CYTOKINES; GENE-EXPRESSION; TNF RECEPTOR; TGF-BETA; INTERLEUKIN-7; ACTIVATION;
D O I
10.1007/s10787-022-00992-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Studies have shown that SARS-CoV-2 has the ability to activate and mature proinflammatory cytokines in the body. Cytokine markers are a group of polypeptide signalling molecules that can induce and regulate many cellular biological processes by stimulating cell receptors at the surface. SARS-CoV-2 has been shown to be associated with activation of innate immunity, and an increase in neutrophils, mononuclear phagocytes, and natural killer cells has been observed, as well as a decrease in T cells including CD4+ and CD8. It is noteworthy that during the SARS-CoV-2 infection, an increase in the secretion or production of IL-6 and IL-8 is seen in COVID-19 patients along with a decrease in CD4+ and CD8+ and T cells in general. SARS-CoV-2 has been shown to significantly increase Th2, Th1/Th17 cells and antibody production in the body of patients with COVID-19. Specific immune profiles of SARS-CoV-2 infection can lead to secondary infections and dysfunction of various organs in the body. It has been shown that Interleukins (such as IL-1, IL-4, IL-6, IL-7, IL-10, IL-12, IL-17, and IL-18), IFN-gamma, TNF-alpha,TGF-beta and NF-kappa B play major roles in the body's inflammatory response to SARS-CoV-2 infection. The most important goal of this review is to study the role of inflammatory cytokines in COVID-19.
引用
收藏
页码:789 / 798
页数:10
相关论文
共 146 条
[1]   Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19 [J].
Adamo, Sarah ;
Chevrier, Stephane ;
Cervia, Carlo ;
Zurbuchen, Yves ;
Raeber, Miro E. ;
Yang, Liliane ;
Sivapatham, Sujana ;
Jacobs, Andrea ;
Baechli, Esther ;
Rudiger, Alain ;
Stussi-Helbling, Melina ;
Huber, Lars C. ;
Schaer, Dominik J. ;
Bodenmiller, Bernd ;
Boyman, Onur ;
Nilsson, Jakob .
ALLERGY, 2021, 76 (09) :2866-2881
[2]  
Al-Rawi MAA, 2003, HISTOL HISTOPATHOL, V18, P911, DOI 10.14670/HH-18.911
[3]  
Alegbeleye Bamidele Johnson, 2020, Iberoam J Med, V2, P335, DOI 10.5281/zenodo.3970519
[4]   IL-17 Signaling: The Yin and the Yang [J].
Amatya, Nilesh ;
Garg, Abhishek V. ;
Gaffen, Sarah L. .
TRENDS IN IMMUNOLOGY, 2017, 38 (05) :310-322
[5]   Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans [J].
Arunachalam, Prabhu S. ;
Wimmers, Florian ;
Mok, Chris Ka Pun ;
Perera, Ranawaka A. P. M. ;
Scott, Madeleine ;
Hagan, Thomas ;
Sigal, Natalia ;
Feng, Yupeng ;
Bristow, Laurel ;
Tsang, Owen Tak-Yin ;
Wagh, Dhananjay ;
Coller, John ;
Pellegrini, Kathryn L. ;
Kazmin, Dmitri ;
Alaaeddine, Ghina ;
Leung, Wai Shing ;
Chan, Jacky Man Chun ;
Chik, Thomas Shiu Hong ;
Choi, Chris Yau Chung ;
Huerta, Christopher ;
McCullough, Michele Paine ;
Lv, Huibin ;
Anderson, Evan ;
Edupuganti, Srilatha ;
Upadhyay, Amit A. ;
Bosinger, Steve E. ;
Maecker, Holden Terry ;
Khatri, Purvesh ;
Rouphael, Nadine ;
Peiris, Malik ;
Pulendran, Bali .
SCIENCE, 2020, 369 (6508) :1210-+
[6]   IL-6 modulation for COVID-19: the right patients at the right time? [J].
Ascierto, Paolo Antonio ;
Fu, Binqing ;
Wei, Haiming .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (04)
[7]   Baricitinib: From Rheumatoid Arthritis to COVID-19 [J].
Assadiasl, Sara ;
Fatahi, Yousef ;
Mosharmovahed, Banafsheh ;
Mohebbi, Bahareh ;
Nicknam, Mohammad Hossein .
JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (10) :1274-1285
[8]   Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study [J].
Avdeev, Sergey N. ;
V. Trushenko, Natalia ;
Tsareva, Natalia A. ;
Yaroshetskiy, Andrey I. ;
Merzhoeva, Zamira M. ;
Nuralieva, Galia S. ;
V. Nekludova, Galina ;
Chikina, Svetlana Yu. ;
Gneusheva, Tatiana Yu. ;
Suvorova, Olga A. ;
Shmidt, Anna E. .
CYTOKINE, 2021, 146
[9]   The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19 [J].
Bagca, Bakiye Goker ;
Avci, Cigir Biray .
CYTOKINE & GROWTH FACTOR REVIEWS, 2020, 54 :51-61
[10]   Activation of type III nitric oxide synthase in astrocytes following a neurotropic viral infection [J].
Barna, M ;
Komatsu, T ;
Reiss, CS .
VIROLOGY, 1996, 223 (02) :331-343